Is quantitative coronary angiography reliable in assessing the late lumen loss of the everolimus-eluting bioresorbable polylactide scaffold in comparison with the cobalt-chromium metallic stent?
EuroIntervention 2017;13:e585-e594 published online March 2017 published online e-edition August 2017. DOI: 10.4244/EIJ-D-17-00070
Yohei Sotomi1, MD; Yoshinobu Onuma2,3, MD, PhD; Yosuke Miyazaki2, MD, PhD; Taku Asano1, MD; Yuki Katagiri1, MD; Erhan Tenekecioglu2, MD; Hans Jonker3, BSc; Jouke Dijkstra4, PhD; Robbert J. de Winter1, MD, PhD; Joanna J. Wykrzykowska1, MD, PhD; Gregg W. Stone5, MD; Jeffrey J. Popma6, MD, PhD; Ken Kozuma7, MD, PhD; Kengo Tanabe8, MD, PhD; Patrick W. Serruys9, MD, PhD; Takeshi Kimura10, MD, PhD
1. Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; 2. Thoraxcenter, Erasmus Medical Center, Rotterdam, the Netherlands; 3. Cardialysis, Rotterdam, the Netherlands; 4. LKEB–Division of Image Processing, Department of Radiology
Aims: Immediately after stent/scaffold implantation, quantitative coronary angiography (QCA) in comparison to optical coherence tomography (OCT) more severely underestimates the lumen dia